Equities researchers at Evercore ISI began coverage on shares of Prothena Corporation PLC (NASDAQ:PRTA) in a research note issued to investors on Wednesday, The Fly reports. The brokerage set an “outperform” rating on the biotechnology company’s stock.

Several other equities research analysts have also recently issued reports on the company. Zacks Investment Research upgraded Prothena Corporation PLC from a “hold” rating to a “buy” rating and set a $66.00 price objective on the stock in a report on Friday, August 11th. BidaskClub cut Prothena Corporation PLC from a “strong-buy” rating to a “buy” rating in a report on Monday, July 31st. Jefferies Group LLC began coverage on Prothena Corporation PLC in a report on Monday, July 10th. They set a “buy” rating and a $100.00 price objective on the stock. Oppenheimer Holdings, Inc. restated an “outperform” rating and set a $70.00 price objective on shares of Prothena Corporation PLC in a report on Thursday, July 6th. Finally, ValuEngine upgraded Prothena Corporation PLC from a “sell” rating to a “hold” rating in a report on Thursday, June 15th. One equities research analyst has rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Prothena Corporation PLC currently has an average rating of “Buy” and a consensus price target of $77.09.

Shares of Prothena Corporation PLC (PRTA) traded down 0.74% during trading on Wednesday, hitting $57.69. The stock had a trading volume of 136,975 shares. Prothena Corporation PLC has a 12-month low of $40.58 and a 12-month high of $69.53. The company’s market cap is $2.21 billion. The stock’s 50 day moving average is $60.53 and its 200-day moving average is $55.14.

Prothena Corporation PLC (NASDAQ:PRTA) last posted its quarterly earnings data on Tuesday, August 8th. The biotechnology company reported ($0.46) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.89) by $0.43. Prothena Corporation PLC had a negative return on equity of 33.20% and a negative net margin of 527.56%. The business had revenue of $26.81 million for the quarter, compared to analysts’ expectations of $16.08 million. During the same quarter last year, the firm earned ($1.18) earnings per share. The business’s revenue was up 7951.1% on a year-over-year basis. Analysts forecast that Prothena Corporation PLC will post ($4.54) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: This news story was published by American Banking News and is the sole property of of American Banking News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.americanbankingnews.com/2017/08/16/prothena-corporation-plc-prta-coverage-initiated-at-evercore-isi.html.

In other Prothena Corporation PLC news, Director Dennis J. Selkoe sold 3,500 shares of the business’s stock in a transaction dated Friday, July 7th. The stock was sold at an average price of $58.11, for a total transaction of $203,385.00. Following the transaction, the director now owns 6,345 shares in the company, valued at $368,707.95. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, insider Karin L. Walker sold 5,000 shares of the business’s stock in a transaction dated Monday, July 17th. The stock was sold at an average price of $64.89, for a total value of $324,450.00. Following the transaction, the insider now owns 5,000 shares in the company, valued at approximately $324,450. The disclosure for this sale can be found here. 3.10% of the stock is currently owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the company. Woodford Investment Management Ltd boosted its position in shares of Prothena Corporation PLC by 2.6% in the second quarter. Woodford Investment Management Ltd now owns 11,400,424 shares of the biotechnology company’s stock worth $616,991,000 after buying an additional 294,213 shares in the last quarter. FMR LLC boosted its position in shares of Prothena Corporation PLC by 0.7% in the second quarter. FMR LLC now owns 5,699,234 shares of the biotechnology company’s stock worth $308,443,000 after buying an additional 39,926 shares in the last quarter. Wellington Management Group LLP boosted its position in shares of Prothena Corporation PLC by 4.6% in the first quarter. Wellington Management Group LLP now owns 3,158,012 shares of the biotechnology company’s stock worth $176,185,000 after buying an additional 138,979 shares in the last quarter. BlackRock Inc. boosted its position in shares of Prothena Corporation PLC by 7.8% in the second quarter. BlackRock Inc. now owns 2,947,512 shares of the biotechnology company’s stock worth $159,519,000 after buying an additional 213,578 shares in the last quarter. Finally, State Street Corp boosted its position in shares of Prothena Corporation PLC by 10.6% in the second quarter. State Street Corp now owns 1,181,365 shares of the biotechnology company’s stock worth $63,932,000 after buying an additional 113,193 shares in the last quarter.

About Prothena Corporation PLC

Prothena Corporation Public Limited Company is a global biotechnology company. The Company is focused on the discovery, development and commercialization of immunotherapies for the treatment of diseases that involve protein misfolding or cell adhesion. The Company’s clinical pipeline of antibody-based product candidates targets a range of indications, including Amyloid Light-chain (AL) amyloidosis (NEOD001), Parkinson’s disease and other related synucleinopathies (PRX002), and inflammatory diseases, including psoriasis and psoriatic arthritis (PRX003) and ATTR amyloidosis (PRX004).

The Fly

Analyst Recommendations for Prothena Corporation PLC (NASDAQ:PRTA)

Receive News & Ratings for Prothena Corporation PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prothena Corporation PLC and related companies with MarketBeat.com's FREE daily email newsletter.